Drugs that contain Fesoterodine Fumarate
1. List of Toviaz drug patents
TOVIAZ Litigations
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6858650 | PFIZER | Stable salts of novel derivatives of 3,3-diphenylpropylamines |
Jul, 2022
(8 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6858650
(Pediatric) | PFIZER | Stable salts of novel derivatives of 3,3-diphenylpropylamines |
Jan, 2023
(2 months ago) | |
| US8501723 | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Jun, 2027
(4 years from now) | |
| US8088398 | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Jun, 2027
(4 years from now) | |
| US7807715 | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Jun, 2027
(4 years from now) | |
|
US7807715
(Pediatric) | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Dec, 2027
(4 years from now) | |
|
US8088398
(Pediatric) | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Dec, 2027
(4 years from now) | |
|
US8501723
(Pediatric) | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Dec, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Indication (I) | Jun 17, 2024 |
| Pediatric Exclusivity (PED) | Dec 17, 2024 |
Market Authorisation Date: 31 October, 2008
Treatment: Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency
Dosage: TABLET, EXTENDED RELEASE;ORAL
How can I launch a generic of TOVIAZ before it's patent expiration?
More Information on Dosage
TOVIAZ family patents
6
United States
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic